COMPANY
FitRX, LLC dba Zealthy
FitRX, LLC dba Zealthy: warning letter recipient for Semaglutide, as stated by public registers.
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Semaglutide | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth), 2025-09-09 Regulator FDA warning letters |
|---|
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.